4.4. CNS stimulants and drugs used for attention deficit hyperactivity disorder
Restrictions: Restricted to specialist initiation for use in ADHD as part of a comprehensive treatment programme only where stimulants are not suitable, not tolerated or have been ineffective.
Restrictions: Restricted to specialist initiation as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.
Restrictions: Modafinil is considered Formulary only for its licensed use in the treatment of excessive sleepiness associated with narcolepsy with or without cataplexy. It is not licensed or approprove for excessive daytime sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome or shift work sleep disorder and these indications are non-Formulary
Restricted to initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD. The modified-release preparations are restricted to second line therapy where there is evidence of compliance problems or where clear evidence that administration of a midday dose is problematic or inappropriate.
Prescribe modified-release preparations by brand name. Xaggitin XL® is the preferred brand of sustained-release methylphenidate
Restrictions: Restricted to second line therapy for the treatment of ADHD and initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD.
Restrictions: Restricted to specialist initiation for the treatment of ADHD in the patient groups listed below. In addition, the oral solution is restricted to use in patients who are unable to swallow capsules.
- In children over 6 years and adolescents who do not respond to stimulants or in whom stimulants are contraindicated or not tolerated (See GGC Paediatric Formulary).
- In adults as part of a comprehensive treatment programme.